Literature DB >> 19846907

Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.

Jason R Gee1, Corrie B Burmeister, Thomas C Havighurst, Kyungmann Kim.   

Abstract

BACKGROUND: Celecoxib and other non-steroidal anti-inflammatory drugs (NSAIDs) are being evaluated in the prevention of bladder and other cancers. Here we investigate molecular effects of celecoxib independent of cyclooxygenase (COX)-2 expression levels in urothelial carcinoma of the bladder.
MATERIALS AND METHODS: Low-grade RT-4 and high-grade UM-UC-3 bladder cancer cells were treated with 0-50 muM celecoxib. Growth, cell cycle and apoptosis were measured by crystal violet elution and flow cytometry. Western analysis was performed for COX-2, Rb, cyclin B1/D1, and phospho-cyclin B1/D1. COX-2 induction was achieved with phorbol ester.
RESULTS: Celecoxib inhibited growth of RT-4 and UM-UC-3, with G(1) cell cycle arrest and altered cyclin B1/D1 expression in RT-4, whereas Rb up-regulation occurred in UM-UC-3. Apoptosis occurred in both cell lines.
CONCLUSION: Celecoxib induces G(1) cell cycle arrest in low- and high-grade bladder cancer by different pathways. This heterogeneous molecular response supports combination approaches to prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846907      PMCID: PMC2955297     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  38 in total

1.  Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.

Authors:  A J Johnson; X song; A Hsu; C Chen
Journal:  Adv Enzyme Regul       Date:  2001

2.  Prostaglandin E2 increases growth and motility of colorectal carcinoma cells.

Authors:  H Sheng; J Shao; M K Washington; R N DuBois
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

Review 3.  Cyclooxygenase-independent actions of cyclooxygenase inhibitors.

Authors:  I Tegeder; J Pfeilschifter; G Geisslinger
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

4.  Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells.

Authors:  M Li; X Wu; X C Xu
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

5.  Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.

Authors:  C J Grubbs; R A Lubet; A T Koki; K M Leahy; J L Masferrer; V E Steele; G J Kelloff; D L Hill; K Seibert
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

Review 6.  Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis.

Authors:  I B Weinstein
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

7.  Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

Authors:  Chris Waskewich; Rosalyn D Blumenthal; Honglan Li; Rhona Stein; David M Goldenberg; Jack Burton
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 8.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.

Authors:  Michael J Thun; S Jane Henley; Carlo Patrono
Journal:  J Natl Cancer Inst       Date:  2002-02-20       Impact factor: 13.506

9.  Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.

Authors:  C S Williams; A J Watson; H Sheng; R Helou; J Shao; R N DuBois
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

10.  The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

Authors:  A L Hsu; T T Ching; D S Wang; X Song; V M Rangnekar; C S Chen
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

View more
  3 in total

1.  A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Authors:  Anita L Sabichi; J Jack Lee; H Barton Grossman; Suyu Liu; Ellen Richmond; Bogdan A Czerniak; Jorge De la Cerda; Craig Eagle; Jaye L Viner; J Lynn Palmer; Seth P Lerner
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

2.  Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.

Authors:  Kuo-How Huang; Kuan-Lin Kuo; Shyh-Chyan Chen; Te-I Weng; Yuan-Ting Chuang; Yu-Chieh Tsai; Yeong-Shiau Pu; Chih-Kang Chiang; Shing-Hwa Liu
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

3.  Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.

Authors:  Sara Tesfazghi; Jacob Eide; Ajitha Dammalapati; Colin Korlesky; Thomas P Wyche; Tim S Bugni; Herbert Chen; Renata Jaskula-Sztul
Journal:  Cancer Med       Date:  2013-09-17       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.